Instructions how to use the ESC teach the teachers course and self-learning tool

Similar documents
Instructions how to use the ESC teach the teachers course and self-learning tool

Time Topic Speaker Abbreviation

Instruction for the patient

What s New in Adolescent Contraception?

Contraception Choices: An Evidence Based Approach Case Study Approach. Susan Hellier PhD, DNP, FNP-BC, CNE

1. Ng M et a l. Global, regional, and national prevalence of overweight and obesity in children and adults during : A systematic analysis

Contraception for Adolescents: What s New?

Medical Eligibility for Contraception Use

Expanding Access to Birth Control: Will Women Get the Care They Need?

Linda Gregg NP, Janet Isabell NP, Sue Montei NP Clinical Reviewers Reproductive Health Unit

2

Contraceptive Updates and Recommendations

Contraceptive Updates and Recommendations

UKMEC SUMMARY TABLE HORMONAL AND INTRAUTERINE CONTRACEPTION

The Doctor Is In. Brent N Davidson MD Vice Chair Women s Health Henry Ford Health System Medical Director Family Planning MDCH

Contraception and gynecological pathologies

Contraception Update: what s new in 2016? Felicity Young MA BSc (Hons) RMN RGN RM NDFSRH A08 Consultant Nurse for Sexual and Reproductive Healthcare

U.S. Medical Eligibility Criteria for Contraceptive Use, 2010

LONG-ACTING REVERSIBLE CONTRACEPTION. Summary Tables

Contraception: Common Problems Faced in Office Practice. Jane S. Sillman, MD Brigham and Women s Hospital

BMI and Contraception: What s the Evidence?

World Health Organization Medical Eligibility for Contraceptive Use. Connie Kraus, PharmD, BCACP Professor (CHS) Director Office of Global Health

LEARNING OBJECTIVES. Beyond the Pill: Long Acting Contraception. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy is Common

Hormonal Contraception: Asian View. Hormonal Contraception: Asian View: focused on Chinese View. Prof.Dr.Xiangyan Ruan, MD.PhD

Ardhanu Kusumanto Oktober Contraception methods for gyne cancer survivors

CURRENT HORMONAL CONTRACEPTION - LIMITATIONS

Contraception for Obese Women RENEE E. MESTAD, MD, MSCI ACOG DISTRICT II UPSTATE MEETING APRIL 29, 2016

LARC: Disclosures. Long Acting Reversible Contraception. Objectives 10/23/2013. I have no relevant financial disclosures

2

Unintended Pregnancy is Common LEARNING OBJECTIVES. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy And Contraceptive Use

Application for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines

CODING GUIDELINES FOR CONTRACEPTIVES. Effective June 1, 2017 Version 1.40

Thrombosis and Women s Health Risk factors, contraceptive pill, HRT and your doctor

Hormonal contraception: NHS Tayside Formulary, pharmacological content and other characteristics

Contraception for young people. Dr Cindy Farmer Bristol Sexual Health Services Fri 8 th May 2015

Learning objectives. Some fun facts. Presenter Disclosure Information. Become familiar with the newest contraceptive options available

When talking about CHC it should not be forgotten that in addition to providing contraception this contraceptive method is associated with additional

Progestin-only methods Type or dose of progestagen

Status Update on the National Cardiovascular Prevention Guidelines - JNC 8, ATP 4, and Obesity 2

Disclosures. Objectives. Case: Anna. Case: Carla. Case: Beth. Contraception (for the Family Physician) 5/22/2015. Valary Gass, MD.

Management of Emergency Contraception (EC)

Contraception. Objectives. Unintended Pregnancy. Unintended Pregnancy in the US. What s the Impact? 10/7/2014

CONTRACEPTION OLD FRIENDS, NEW TRENDS

Levosert levonorgestrel 20mcg/24hour intrauterine device

Learning objectives. Some fun facts. Presenter Disclosure Information. Discuss the newest contraceptive options available

the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD your guide to

The Balanced Counseling Strategy Plus: A Toolkit for Family Planning Service Providers Working in High STI/HIV Prevalence Settings.

Table I. Examples of Hormone and Tapering Regimens

Information for Informed Consent for Insertion of a Mirena IUD

Effective Contraception Utilization. Sarah Laiosa, DO Family Physician Contract Medical Director, EOCCO

2/4/2011. What is your specialty? A. Family practice B. Internal medicine and subs C. OB/GYN D. Peds E. Surgery and subs

prevalence was 13.8% among females

Disclosures. Learning Objectives 4/18/2017 ADOLESCENT CONTRACEPTION UPDATE APRIL 28, Nexplanon trainer for Merck

An Overview of Long Acting Reversible Contraception Methods

One-day Essentials Contraception. Dr Paula Briggs, General Practitioner, Clinical Lead Community Sexual Health, Sefton and West Lancashire

Fertility control: what do women want?

VI.2. ELEMENTS FOR A PUBLIC SUMMARY

Family Planning Eligibility Program

Psychosocial Aspects of Family Planning: Hormonal Contraception and Mood

Contraceptives. Kim Dawson October 2010

FIGO and Prevention of Unsafe Abortion LARC and PM for PAC

Topics. Periods Menopause & HRT Contraception Vulva problems

FDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system)

Risk of venous thromboembolism in users of non-oral contraceptives Statement from the Faculty of Sexual and Reproductive Healthcare

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:

Perimenopausal contraception: A practice-based approach

Contraception for Women and Couples with HIV. Knowledge Test

Female Sterilization. Kavita Nanda, MD, MHS FHI 360 Expanding Contraceptive Choice December 6, 2018

Clinical Challenges in Contraception. Disclosures. Objectives Pharmacists 4/3/2018

1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S.

Elements for a Public Summary. VI.2.1 Overview of Disease Epidemiology

Percentage of family planning clinics, according to clinic characteristics, by service focus, Title X funding status and clinic type, 2010 and 2015

100% Highly effective No cost No side effects

Trudy Bush Lecture: Using Progestins in Clinical Practice. Progestins in Clinical Practice: Outline. NAMS Definitions. FDA Approved Oral Progestins

HRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College

Hormonal contraception and HIV risk

MENOPAUSE / COMPLEX CONTRACEPTION / MEDICAL GYNAECOLOGY CLINICAL SERVICES AT CHALMERS

Nelly Mugo, MBChB, MMed, MPH Kenya Medical Research Institute. May 2015

Birth Control in Patients with Congenital Heart Disease

Birth Control Options Chart

The number of women using long-acting reversible

levonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer

Family Planning UNMET NEED. The Nurse Mildred Radio Talk Shows

International Federation of Gynecology and Obstetrics

Orals,Transdermals, and Other Estrogens in the Perimenopause

for Women Living with HIV Infection

Picking the Perfect Pill How to Effectively Choose an Oral Contraceptive

Contraception. Yolanda Evans MD MPH Assistant Professor of Pediatrics Division of Adolescent Medicine

Birth Control- an Overview. Keith Merritt, MD. Remember, all methods of birth control are safer and have fewer side effects than pregnancy

PERSONAL CHARACTERISTICS AND REPRODUCTIVE HISTORY...3 Pregnancy...3 Age...3 Parity...3 Breastfeeding...3 Postpartum...3 Post-abortion...

Reproductive health research at WHO

Welcome to Mirena. The Mirena Handbook: A Personal Guide to Your New Mirena. mirena.com. Mirena is the #1 prescribed IUD * in the U.S.

Disclosures CONTRACEPTION COUNSELING IN MEDICALLY COMPLEX ADOLESCENTS. Aletha Akers, MD, MPH and Lyndsey Benson, MD, MS

HIV and contraception the latest recommendations

Elements for a Public Summary. Overview of Disease Epidemiology

Notes to Teacher continued Contraceptive Considerations

WHAT ARE CONTRACEPTIVES?

MIDWIVES IN CONTRACEPTION AND FERTILITY PLANNING 15 TH ANNUAL SOMSA CONGRESS BLOEMFONTEIN AUGUST 2018

Simplifying Vide Contraception. University of Utah Department of Ob/Gyn Post Grad Course February 13, 2017 David Turok

Family Planning د. نجمه محمود كلية الطب جامعة بغداد فرع النسائية والتوليد

Transcription:

Instructions how to use the ESC teach the teachers course and self-learning tool Welcome to the ESC advanced learning tool To improve and facilitate knowledge and use of contraception, abortion, sexually transmitted infections and reproductive health care across Europe is the major aim of ESC. By developing this teaching tool ESC aimed to facilitate access to advanced knowledge and provide teaching material for courses especially in countries with insufficient training options. This ESC-teaching tool and self-learning course fills a gap. It adds specialised and updated knowledge to the WHO teaching course (www.fptraining.org). The tool has been prepared by five authors experienced in contraception and evidence based medicine. The concept of this advanced training tool was to create slide sessions with notes, which can be used for teaching, but also for self-study. The training tool does not provide new guidelines but intends to enable the doctor to understand the background of WHO MEC, to identify women at increased risk for complications and to understand options to reduce adverse events and complications. This should facilitate and improve contraceptive counselling in daily but also difficult situations. Content of the slides is based on new evidence and references are given for more interested doctors. The tool also includes five sessions about contraception in women with medical Instructions - 1

conditions. As this is an advanced learning tool we recommend less experienced nurses and doctors to first study the WHO training tools (www.fptraining.org), This self-study concept allows all ESC members to use the tool for self-training and update their knowledge around contraceptive methods Having studied this tool or visited a course based on this tool should Enable you to take a complete history of factors important for contraceptive counselling Improve your understanding of risks and benefits associated with use of CHC and different types of CHC Enable you to identify women with cardiovascular and other risk factors for serious adverse events Enable you to a balanced counselling in patients with cardiovascular risk factors based on exact numbers of potential events Improve your counselling skill with regard to differentiate between different types of POC and understand the differences in bleeding patterns and side effects, also in comparison with CHC Improve your counselling skill with regard to differentiate between different types of IUD Improve your counselling skill with regard to harmless and harmful side effects for all women and adolescents who want to use an IUD Improve your counselling skill for patients with difficult medical conditions and / or use of enzyme inducing drugs Improve your counselling skill for permanent methods (male and female options) A successful use of this tool is only possible, if the teacher or user has studied and is familiar with the WHO training tool. The broad information given in the slide notes allows better understanding of the background of the key messages. Lots of references are provided for those who want to go deeper into a topic. The Kahoot test, also based on advanced knowledge, will give you an overview if you picked up the key messages of the course. Instructions - 2

Practical considerations for courses Teaching of all topics included will need around two days. We would recommend to give a short introduction to the WHO/MEC in the beginning and ask participants to study the WHO training tool (www.fptraining.org) in advance. Plan after each session 10 minutes for questions, and discussions. According to your needs and the available time for a course you could also select some topics of the tool for a half-day or one day course. Teaching the 4 CHC sessions, 5 MC sessions, the IUD sessions and POP sessions will need half a day each. For permanent methods 40 minutes should be reserved. Our experience shows that the practical work on cases is very helpful. Spending twenty to thirty minutes for one case is recommended. The authors of this ESC tool will help you with organising and planning courses, whenever possible. Planning enough in advance will increase the probability for us to participate as a speaker. ESC members can apply for financial support for courses: http://www.escrh.eu/education/grants. Gabriele Merki ESC President Instructions - 3

Overview Sessions and Cases Topic Combined hormonal contraceptives Combined hormonal contraceptives Combined hormonal contraceptives Combined vaginal ring, combined transdermal patch Case Workshops Case 1: CHC history risks Case 2 : CHC history Medical condition: Mental disabilities Eating disorders Progestin only contraceptives overview Progestin only pill with desogestrel and Depot medroxyprogesterone acetate (DMPA) Etonogestrel-releasing implant Medical condition: Obesity and family history for VTE Workshop 2 Case 1 : breastfeeding and obesity Case 2 : POC and bleeding Medical condition: 1.Contraception in women with HIV infection 2.Hormonal contraceptives and drug interactions Intrauterine devices overview Copper-IUDs Levonorgestrel releasing intrauterine system IUDs in special situations Medical condition: Migraine and depression Female and male sterilisation Workshop 3 Case 1: Permanent methods Case 2 : LNG-IUS abortion-dysmenorrhoea Medical Condition: Hormonal contraception and Breast and ovarian Cancer BRCA1/BRCA2 carriers Workshop 4 Case 1: Non-oral CHCs (15 min) Case 2: POC-Breastfeeding-EC (15 min) Case 3: STD and IUD (30 min) Contraception after abortion Kahoot quiz / discussion of responses Abbreviation in slides CHC I CHC II CHC III CHC IV: CVR,CTP WS 1 MC Mental disorders POC Overview POP and DMPA POC Implant MC Obesity, family history and VTE WS 2 MC Women with HIV CHC and Drug interactions IUD Overview Copper-IUDs LNG-IUS IUDs in special situations MC Migraine and depression Female and male sterilisation WS 3 MC CHC breast and ovarian cancer WS 4 Contraception after abortion Separate file Open discussion / evaluation 6 November 2018 Contents - 4

1. Content of each session CHC I Clinical relevant metabolic effects of ethinylestradiol (EE) The variations in individual steroid plasma levels and potential clinical consequences The difference between the mostly used progestins in CHCs Typical properties of progestins Types and dosages of CHCs Clinical effects of a lower EE dosage Difference between pills with estradiol /estradiolvalerate and EE CHC II How to take a history before contraceptive counseling Special risk screening for use of CHCs (higher risks/ lower risks and WHO MEC category 4 criteria criteria) There are two types of risks one affecting the arterial system and one the venous system VTE risk in healthy young women without contraception and in pregnancy o EMAS recommendation: VTE risk according to progestin type and method of application o VTE risk according to estrogen dose and type of estrogen o Understand what is meant by a positive family history and what it means for risk counselling o VTE risk in women with thrombophilia o Overview risk for VTE in numbers and multiplication of risks o VTE risk with age, obesity and duration of CHC use Arterial risk: stroke and myocardial infarction in numbers, in relation to age and obesity Balancing risks against other contraceptive options and benefits during counselling 6 November 2018 Contents - 5

CHC III Contraceptive health benefits of CHCs Minor harmless side effects Treatment of side effects Major side effects / reasons to stop pill immediately VTE risk in newstarters and counselling for symptoms associated with DVT and PE Pill return visit Measurement of blood pressure CHC IV: CVR,CTP Description and formulation; Application Pharmacokinetics; Regimen of use Similarities ring, patch and pill; Advantages ring and patch > pill Contraceptive failure rates Dosing errors; Extended use Concurrent use Cycle control; Acceptability; Compliance; Side effects compared with pill Device-related problems; Acceptability ring vs patch Venous and arterial thromboembolism Counselling MC Mental disorders General considerations Feeding and eating disorders Psychotic disorders Some aspects of contraception in disabled women POC Overview Progestin types Working mechanism Contraceptive efficacy and safety of POC Use in women with medical conditions Health benefits Adverse events: bleeding, breast tenderness, weight, acne, BMD 6 November 2018 Contents - 6

POP and DMPA POP General characteristics of the desogestrel 75 µg POP Mechanism of action Contraceptive efficacy Health benefits, migraine Side effects, bleeding Emergency contraception Breastfeeding Summary DMPA General characteristics of DMPA Contraceptive efficacy and duration of use Mechanism of action Contraindications Health benefits Safety Side effects and treatment Reasons for discontinuation Summary POC Implant General characteristics of the ENG-releasing implant Mechanism of action Contraceptive efficacy Health benefits Contraindications Side effects and treatment, continuation Summary MC Obesity, family history and VTE Obesity Definition of obesity Obesity and VTE risk Which contraceptives are efficient in obese women Contraception after bariatric surgery Family history and VTE Contraception after VTE Definition of positive family history for VTE Efficient and safe contraception if FH is positive VTE risk in women with positive FH 6 November 2018 Contents - 7

MC Women with HIV CHC and Drug interactions HIV Main characteristics of HIV infection, classification and clinical stages of HIV infection Concerns regarding contraception: o Drug interaction o Possible impact on progression of HIV infection o Impact on HIV transmission and acquisition o Potential risks related to HIV infection/aids Hormonal contraceptives and drug interactions Overview of the metabolism of the contraceptive steroids Pharmacokinetic drug interaction Interactions of CHC and POC with: o anti-epileptic drugs o psychotropic drugs o herbal remedies o antimicrobial therapy IUD Overview Types of IUD Efficacy of IUDs and duration of use IUDs and PID risk, screening for STIs prior to insertion Need for antibiotic prophylaxis during insertion Pain management during IUD insertion When to insert (after abortion and pregnancy), switching from another method Risk factors, frequency of expulsion and dislocation, reinsertion after expulsion Post-insertion visit Copper-IUDs Mechanism of action Efficacy, duration of use Side effects: harmless, harmful, frequency Treatment of side effect Contraindications Misconceptions Counseling Risk of ectopic pregnancy Copper ball and expulsion 6 November 2018 Contents - 8

LNG-IUS What is the hormone-releasing intrauterine system (IUS) and why was it developed General characteristics of the LNG-IUS Mechanism of action Contraceptive efficacy and duration of use Side effects: harmless and harmful, treatment Reasons for discontinuation Medical indications for LNG-IUS use IUDs in special situations Adolescents Risk of cervical cancer risk (LSIL and HSIL) Women after STI or at increased risk of STI IUDs and cardiovascular disease Women with HIV Women with immunosuppression MC Migraine and depression Migraine Sex differences in epidemiology of migraine Prevalence of migraine Background of hormonal triggers for migraine Basics on diagnostic criteria for migraine WHO recommendation for CHC use in migraineurs Association between migraine and stroke When to stop CHCs in migraineurs Contraceptive options for migraineurs Depression Definition of depression Prevalence in Europe How not to miss depression in taking a history Potential effects of contraceptive methods on the course of depression in women with depression as a pre-existing condition Which contraceptives may cause depressed mood Female and male sterilisation Female sterilisation Introduction Surgical planning Postpartum sterilisation Interval sterilisation Laparoscopic sterilisation 6 November 2018 Contents - 9

Hysteroscopic sterilisation Essure Preoperative counselling Contraceptive failure rates Causes of failed sterilisation Potential post-sterilisation effects Risk of regret Opportunistic bilateral salpingectomy Male sterilisation Introduction Procedures and techniques Postoperative care Confirmation of sterility Contraceptive failure rates Contraindications Complications Associated morbidity concerns Counselling Vasectomy reversal MC CHC breast and ovarian cancer Effect of CHC on breast cancer risk Effect of CHC on ovarian cancer risk CHC and breast cancer risk in women with hereditary breast cancer CHC and ovarian cancer risk in carriers of BRCA1/BRCA2 mutations CHC and breast cancer risk in carriers of BRCA1/BRCA2 mutations Contraceptive options for women after breast cancer Contraception after abortion Background : Return of fertility after abortion Background: VTE risk during first and second trimester pregnancy WHO Medical eligibility criteria for contraceptive use after abortion When to initiate contraception after first trimester abortion IUD insertion after medical abortion When to initiate contraception after second trimester medical and surgical abortion 6 November 2018 Contents - 10

2. List of abbreviations AOR ART ATE BN BMD BSO CD CHC COC Copper-IUD CTP CVR CVT DMPA DRSP DSG DVT E2 EE EMA ENG EV FH FS GSD HC HMB IUD LNG LNG-IUS MI NGMN NOMAC OR PE PID PND POC POP PrEP RCT SHBG STI TL UPA VD VTE adjusted odds ratio antiretroviral therapy arterial thromboembolic event bulimia nervosa bone mineral density bilateral salpingectomy caesarean delivery combined hormonal contraceptives combined oral contraceptives copper releasing devices combined transdermal patch combined vaginal ring cerebral venous thrombosis depo-medroxyprogesterone acetate drospirenone desogestrel deep venous thrombosis estradiol ethinylestradiol European Medical Agency etonogestrel estradiolvalerate family history female sterilisation gestoden hormonal contraceptives heavy menstrual bleeding intrauterine device Levonorgestrel Levonorgestrel-releasing intrauterine device (Mirena ) myocardial infarction norelgestromin nomegestrol acetate odd ratio pulmonary embolism pelvic inflammatory disease postnatal depression progestin-only contraceptive progestin-only pill (includes only desogestrel 75 µg in our project) pre-exposure prophylaxis randomised controlled trials sexual hormone binding globulin sexual transmitted disease tubal ligation ulipristal acetate vaginal delivery venous thromboembolism 6 November 2018 Abbreviations - 11

3. Authors of the training tool Bombas Teresa, Portugal Present position MD, Consultant in Gynecology and Obstetrician at Obstetric Service A. Centro Hospitalar e Universitário de Coimbra. Portugal Responsible for the outpatient clinic on FP and abortion at Obstetric Service A. Centro Hospitalar e Universitário de Coimbra. Portugal Current and earlier tasks in ESC Member of Internal Scientific Committee of the European Society of Contraception and Reproductive Health (ESC) Member of ESC Expert Group on Sexual Medicine and Sex Education Lete Lasa Luis Ignacio, Spain Present position Head of Obstetrics and Gynecologic Department. University Hospital Araba. Vitoria. Spain Professor of Obstetrics and Gynecology. Basque Country University Current and earlier tasks in ESC Deputy Editor of the European Journal of Contraception and Reproductive Health Care Past member of Board 6 November 2018 Faculty - 12

Merki Gabriele, Switzerland Present position Head of Family Planning and Adolescent Gynaecology, Clinic for Reproductive Endocrinology, University Hospital Zürich, Switzerland Current and earlier tasks in ESC Current: o President o Board representative for Switzerland Earlier: o Vice-President o Board Member o Member of the Internal Scientific Committee o Member of the Expert Group on hormonal contraception o Co-organiser of the 2016 Basel Congress Roumen Frans J.M.E., the Netherlands Present position Gynaecologist Zuyderland Medical Centre, Heerlen, The Netherlands Current and earlier tasks in ESC Editor European Journal of Contraception and Reproductive Health Care Vice-president local organizing committee ESC Congress, The Hague, 2010 Sedlecky Katarina, Serbia 6 November 2018 Faculty - 13

Present position M.D., PhD, specialist of obstetrics and gynaecology Senior adviser in the Family Planning Centre, Institute for Mother and Child Health Care of Serbia, Belgrade Current and earlier tasks in ESC Board member 2006-2014 Executive committee member: o Assistant treasurer 2008-2010 o Secretary general 2010-2014 Member of ESC Expert Group on Sexual Medicine and Sex Education 2014-6 November 2018 Faculty - 14

4. Instructions how to use the cases in workshops Group discussion cases Introduction Though effective presentations are important, even more important is communicating well in group settings because that is where most work is completed. In this exercise, you ll work in a group of 5-6 individuals to resolve several realistic patient problems on contraception as you ll encounter in your daily practice. Purpose To inform adequately and evidence-based the woman with questions on her specific contraceptive problem and to provide her with a tailor-made contraceptive advice in an open communication. Roles ESC-Teacher: has two roles: He/she is the patient and answers questions associated to the medical case He/she guides the group discussion and watches the time schedule For this purpose, she/he studies the information on the patients situation and her key issues. She/he puts questions to the participants, provides information on the condition of the patient, evaluates the given answers, and provides suggestions for improvement. Participants: have the role of the doctor They start with reading the information given on the specific case (Instructions for the doctor and information slides). They answer questions of the patient (ESC teacher), ask questions about the personal situation, risk factors and medical conditions of the patient, balance benefits and risks for the patient, and provide a tailor-made contraceptive advice. Learning targets WS 1: to learn to take a complete history: to identify risk factors and other important aspects needed as background for contraceptive counselling. The task of the group is to find out all the details of the patient and to answer all the questions of the patient. WS 2-4: here the aim is not the comprehensive and detailed history. Therefore, the patient / ESC teacher may give a lot of information of the patients situation to not loose time for the history and to focus on the content of the cases. He/she can individually vary this according to the time available. 6 November 2018 Instructions workshops - 15

WS 2: contraception during breastfeeding, WHO criteria for breastfeeding, contraception and obesity, POC, especially implant and bleeding pattern, treatment and counselling in situations of bleeding irregularities, role of weight, obesity and age as risk factor. WS 3: permanent methods, post-abortion contraception, counselling of LARC. WS 4: aim is repetition: Patch/Ring, bulimia, POP, MEC breast feeding, efficacy, missing a pill, frequency of adverse events with different methods, UPA and interaction with COC and POP, IUS and PID. 6 November 2018 Instructions workshops - 16